Kabutaro's purchase
Purchase date: 2026-08-14
Amount: JPY 270,000
Quantity: 27 units
Price per unit: JPY 10,000
Type: FUNDINNO-type paid stock acquisition rights
Angel tax scheme: Not eligible
Basic information
Company: DFree Inc.
Field: Development and sale of an excretion prediction device
Listing status: Unlisted (has signed with an audit firm and a lead underwriter)
Links
FUNDINNO project page (Japanese)
This page is a translation of the Japanese page, which is updated first: Japanese version
Company profile
Founded: February 2015
Head office: Minato, Tokyo
Representative: Atsushi Nakanishi, CEO
Capital: JPY 75,000,000 (as of May 11, 2026)
Offering terms
Target amount: JPY 10,080,000
Maximum amount: JPY 99,990,000
Shareholder benefits
Holders of the stock acquisition rights get a discount on the company's products.
・1–19 units: 5% off
・20 units or more: 10% off
With 27 units, Kabutaro gets 10% off.
Business
DFree develops and sells a device that uses an ultrasound sensor on the abdomen and AI to predict when a person needs to go to the toilet, easing the burden of toileting care at nursing homes and at home. The Maezawa Fund has also invested.
・Adoption: Used at 383 facilities. Some cut diaper costs by 50% and urination care time by 150 hours
・Products: Models for home use, for facilities, and a light 20 g model
・Technology: 10 patents held and 6 pending. Selected by NEDO, AMED and J-Startup
Notes
FUNDINNO investments are unlisted shares, so they cannot be sold until the company lists or is acquired. Company details and plans are based on the FUNDINNO project page and the company's announcements.
Current status
Listing / M&A: –
Valuation: –
Related pages: IPO / Trade History / Annual Results